Physician profile
Ting Wei
NPI 1861999773
$5,324.45
in general payments reported to CMS, 2019-2025
29 companies · $793 in 2025
The $793 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,348 · 2023: $2,525 · 2024: $659 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,774 · Travel and Lodging: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,774.15 |
| Travel and Lodging | $1,202.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,988.40 | 2022-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Bioventus LLC | $1,087.90 | 2023 | Stimrouter Implantable Kit |
| Spr Therapeutics, INC | $435.74 | 2022-2025 | Sprint Pns System |
| Nevro Corp. | $350.41 | 2023-2024 | Senza |
| Boston Scientific Corporation | $116.42 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $116.18 | 2024-2025 | Lumryz |
| Averitas Pharma INC. | $101.13 | 2023-2025 | Qutenza |
| Abbott Laboratories | $99.87 | 2023-2024 | Eterna, Proclaim |
| Painteq LLC | $92.26 | 2023-2024 | Painteq |
| Vertex Pharmaceuticals Incorporated | $91.95 | 2024-2025 | |
| Ucb, INC. | $85.52 | 2023-2025 | Briviact, Zilbrysq, Rystiggo |
| Jazz Pharmaceuticals INC. | $82.31 | 2025 | |
| Azurity Pharmaceuticals, INC. | $82.05 | 2024-2025 | Horizant |
| Collegium Pharmaceutical, INC. | $80.13 | 2023-2024 | Belbuca, Xtampza |
| Saluda Medical Americas, INC. | $60.73 | 2024 | Evoke |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $57.44 | 2025 | |
| Si-Bone, INC. | $54.87 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $53.74 | 2025 | Austedo Xr |
| Vertos Medical, INC. | $43.96 | 2023 | Mild Device Kit |
| Abbvie INC. | $35.61 | 2024 | |
| Sk Life Science, INC. | $35.26 | 2024-2025 | |
| Valinor Pharma, LLC | $31.43 | 2025 | Movantik |
| Lilly USA, LLC | $30.33 | 2023 | Emgality |
| Scilex Pharmaceuticals INC. | $22.63 | 2025 | |
| Neurelis, INC. | $20.72 | 2025 | Valtoco |
| Globus Medical, INC. | $19.61 | 2025 | Vyrsa V1 |
| Genentech USA, INC. | $19.17 | 2025 | Ocrevus Zunovo |
| Pfizer INC. | $14.56 | 2024 | |
| Lundbeck LLC | $14.12 | 2025 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ting Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.